GIP and metabolic dysfunction-associated steatotic liver disease: Another class of drugs with potential effects on MASLD is represented by tirzepatide, which combines the action of both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist [248].